Multiple sclerosis and Guillain-Barré syndrome have many things in common. Find out how the two conditions compare. ... Doctors don't know exactly what causes MS, GBS, or CIDP.

Neuromuscular disorders affect the nerves that control certain muscles in your body. Some examples include amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Neuromuscular disorders ...

CIDP shares some similarities to other neurological disorders, such as GBS and MS. It is important to get the correct diagnosis to receive proper treatments.

CIDP gets worse more slowly and often lingers for several months or even years. Both multiple sclerosis and CIDP involve damage to the sheath that surrounds nerves, called myelin.

Some patients with CIDP exhibit either subclinical involvement of the CNS with diffuse asymptomatic demyelination , 31 or an associated multiple sclerosis (MS)-like condition. 32 CIDP can also ...

"EC approves argenx’s efgartigimod alfa for CIDP treatment" was originally created and published by Pharmaceutical Technology ...

Investigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP). "Despite the fact that we have some good standard-of-care therapies ...

The authors conducted a multicenter randomized, double-blind trial from hospitals in the Netherlands between April 2014 and November 2018 with patients who had probable or definite CIDP, had been ...

Meanwhile, initial data from 73 patients who took part in its Phase 2b CIDP study suggested a 1.8-point improvement in a ...

Other CIDP scales also demonstrated meaningful improvements for pooled batoclimab cohorts, with an improvement in I-RODS of 15.3, an improvement in MRC-SS of 5.6, and an improvement in grip ...

Immunovant does not intend to seek regulatory approval for batoclimab in MG or CIDP and is focused on leveraging data and learnings from the batoclimab studies to accelerate programs with IMVT-1402.